Physician profile
David Reisman
NPI 1285710152
$2,441.21
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.75 · 2022: $1,233 · 2023: $1,128 · 2024: $30.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $310.73 | 2019-2023 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $260.50 | 2019-2023 | Kisqali, Piqray |
| E.R. Squibb & Sons, L.L.C. | $177.39 | 2022-2024 | Opdivo, Augtyro, Opdualag |
| Amgen INC. | $173.50 | 2022-2023 | Vectibix, Xgeva, Nplate |
| Merck Sharp & Dohme LLC | $164.92 | 2022-2023 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $131.68 | 2022-2023 | Enhertu, Injectafer |
| Pfizer INC. | $125.00 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $119.05 | 2022-2023 | Libtayo |
| Beigene USA, INC. | $110.62 | 2022-2023 | Brukinsa |
| Janssen Biotech, INC. | $104.34 | 2022-2023 | Erleada |
| Astrazeneca Pharmaceuticals LP | $78.50 | 2022 | |
| Abbvie INC. | $73.93 | 2022-2023 | |
| Genzyme Corporation | $66.72 | 2022-2023 | |
| Eisai INC. | $49.86 | 2022-2023 | |
| Stemline Therapeutics INC. | $42.09 | 2023 | Orserdu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $39.42 | 2023 | Clonoseq |
| Genentech USA, INC. | $32.79 | 2022-2023 | Venclexta |
| Sumitomo Pharma America, INC. | $31.42 | 2023 | Orgovyx |
| Seagen INC. | $26.22 | 2022 | |
| Recordati_rare_diseases_inc. | $24.70 | 2023 | Sylvant |
| Lilly USA, LLC | $24.10 | 2023 | Verzenio, Jaypirca |
| Genmab U.S., INC. | $23.63 | 2023 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $23.61 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.21 | 2023 | Ninlaro |
| Aveo Pharmaceuticals, INC. | $20.78 | 2023 | Fotivda |
| Karyopharm Therapeutics INC. | $20.06 | 2023 | Xpovio |
| Octapharma USA, INC. | $19.67 | 2022 | |
| G1 Therapeutics, INC. | $18.71 | 2023 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $17.31 | 2022 | |
| Global Blood Therapeutics, INC. | $17.24 | 2022 | |
| Incyte Corporation | $16.09 | 2022 | |
| Astellas Pharma US INC | $15.85 | 2023 | Xospata |
| Rigel Pharmaceuticals, INC. | $15.41 | 2019 | |
| Exelixis INC. | $14.84 | 2022 | |
| Myovant Sciences INC. | $14.19 | 2022 | |
| Emd Serono, INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.